Next Generation Sequencing Fda Issues New

Respondents' Motion In Limine to Excluse Expert Testimony ...

alternative next generation sequencing (“NGS”) platforms, and on issues relating to regulatory and reimbursement issues; (2) she improperly summarizes the testimony and documentary evidence from third parties; and, (3) she improperly weighs the evidence.

  Next, Generation, Issue, Sequencing, Next generation sequencing